154 related articles for article (PubMed ID: 27335730)
1. Early breast cancer screening using iron/iron oxide-based nanoplatforms with sub-femtomolar limits of detection.
Udukala DN; Wang H; Wendel SO; Malalasekera AP; Samarakoon TN; Yapa AS; Abayaweera G; Basel MT; Maynez P; Ortega R; Toledo Y; Bossmann L; Robinson C; Janik KE; Koper OB; Li P; Motamedi M; Higgins DA; Gadbury G; Zhu G; Troyer DL; Bossmann SH
Beilstein J Nanotechnol; 2016; 7():364-373. PubMed ID: 27335730
[TBL] [Abstract][Full Text] [Related]
2. Early detection of pancreatic cancers in liquid biopsies by ultrasensitive fluorescence nanobiosensors.
Kalubowilage M; Covarrubias-Zambrano O; Malalasekera AP; Wendel SO; Wang H; Yapa AS; Chlebanowski L; Toledo Y; Ortega R; Janik KE; Shrestha TB; Culbertson CT; Kasi A; Williamson S; Troyer DL; Bossmann SH
Nanomedicine; 2018 Aug; 14(6):1823-1832. PubMed ID: 29782949
[TBL] [Abstract][Full Text] [Related]
3. Nanoplatforms for highly sensitive fluorescence detection of cancer-related proteases.
Wang H; Udukala DN; Samarakoon TN; Basel MT; Kalita M; Abayaweera G; Manawadu H; Malalasekera A; Robinson C; Villanueva D; Maynez P; Bossmann L; Riedy E; Barriga J; Wang N; Li P; Higgins DA; Zhu G; Troyer DL; Bossmann SH
Photochem Photobiol Sci; 2014 Feb; 13(2):231-40. PubMed ID: 24096539
[TBL] [Abstract][Full Text] [Related]
4. Inhibitors of proteases as anticancer drugs.
Jedinak A; Maliar T
Neoplasma; 2005; 52(3):185-92. PubMed ID: 15875078
[TBL] [Abstract][Full Text] [Related]
5. Effective activation of the proenzyme form of the urokinase-type plasminogen activator (pro-uPA) by the cysteine protease cathepsin L.
Goretzki L; Schmitt M; Mann K; Calvete J; Chucholowski N; Kramer M; Günzler WA; Jänicke F; Graeff H
FEBS Lett; 1992 Feb; 297(1-2):112-8. PubMed ID: 1551416
[TBL] [Abstract][Full Text] [Related]
6. Urokinase-type plasminogen activator (uPA) and its receptor (CD87): a new target in tumor invasion and metastasis.
Schmitt M; Wilhelm O; Jänicke F; Magdolen V; Reuning U; Ohi H; Moniwa N; Kobayashi H; Weidle U; Graeff H
J Obstet Gynaecol (Tokyo 1995); 1995 Apr; 21(2):151-65. PubMed ID: 8556577
[TBL] [Abstract][Full Text] [Related]
7. Protease nexin-1 expression is altered in human breast cancer.
Candia BJ; Hines WC; Heaphy CM; Griffith JK; Orlando RA
Cancer Cell Int; 2006 May; 6():16. PubMed ID: 16737540
[TBL] [Abstract][Full Text] [Related]
8. The urokinase plasminogen activator system in breast cancer invasion and metastasis.
Tang L; Han X
Biomed Pharmacother; 2013 Mar; 67(2):179-82. PubMed ID: 23201006
[TBL] [Abstract][Full Text] [Related]
9. Increased levels of cathepsin B and L, urokinase-type plasminogen activator and its inhibitor type-1 as an early event in gastric carcinogenesis.
Farinati F; Herszényi L; Plebani M; Carraro P; De Paoli M; Cardin R; Roveroni G; Rugge M; Nitti D; Grigioni WF; D'Errico A; Naccarato R
Carcinogenesis; 1996 Dec; 17(12):2581-7. PubMed ID: 9006092
[TBL] [Abstract][Full Text] [Related]
10. [The role of cathepsins and the plasminogen activator/inhibitor system in colorectal cancer].
Herszényi L; Farinati F; Plebani M; István G; Sápi Z; Carraro P; De Paoli M; Naccarato R; Tulassay Z
Orv Hetil; 1999 Aug; 140(33):1833-6. PubMed ID: 10489782
[TBL] [Abstract][Full Text] [Related]
11. Tumour-associated fibrinolysis: the prognostic relevance of plasminogen activators uPA and tPA in human breast cancer.
Schmitt M; Jänicke F; Graeff H
Blood Coagul Fibrinolysis; 1990 Dec; 1(6):695-702. PubMed ID: 2133250
[TBL] [Abstract][Full Text] [Related]
12. The urokinase-system in tumor tissue stroma of the breast and breast cancer cell invasion.
Hildenbrand R; Schaaf A
Int J Oncol; 2009 Jan; 34(1):15-23. PubMed ID: 19082473
[TBL] [Abstract][Full Text] [Related]
13. Cysteine and serine proteases in gastric cancer.
Plebani M; Herszènyi L; Cardin R; Roveroni G; Carraro P; Paoli MD; Rugge M; Grigioni WF; Nitti D; Naccarato R
Cancer; 1995 Aug; 76(3):367-75. PubMed ID: 8625115
[TBL] [Abstract][Full Text] [Related]
14. Increased expression of matrix metalloproteinases (MMP)-2, MMP-9, and the urokinase-type plasminogen activator is associated with progression from benign to advanced ovarian cancer.
Schmalfeldt B; Prechtel D; Härting K; Späthe K; Rutke S; Konik E; Fridman R; Berger U; Schmitt M; Kuhn W; Lengyel E
Clin Cancer Res; 2001 Aug; 7(8):2396-404. PubMed ID: 11489818
[TBL] [Abstract][Full Text] [Related]
15. Monitoring of chemotherapy successfulness of platina/taxol chemotherapy protocol by using determination of serum urokinase plasminogen activator (uPA) and soluble urokinase plasminogen activator receptor (suPAR) in patients with ovarian carcinoma FIGO II and III stage.
Ljuca D; Fatusić Z; Iljazović E; Ahmetović B
Bosn J Basic Med Sci; 2007 May; 7(2):111-6. PubMed ID: 17489744
[TBL] [Abstract][Full Text] [Related]
16. Quantitative RT-PCR assays for the determination of urokinase-type plasminogen activator and plasminogen activator inhibitor type 1 mRNA in primary tumor tissue of breast cancer patients: comparison to antigen quantification by ELISA.
Biermann JC; Holzscheiter L; Kotzsch M; Luther T; Kiechle-Bahat M; Sweep FC; Span PN; Schmitt M; Magdolen V
Int J Mol Med; 2008 Feb; 21(2):251-9. PubMed ID: 18204793
[TBL] [Abstract][Full Text] [Related]
17. Procedures for the quantitative protein determination of urokinase and its inhibitor, PAI-1, in human breast cancer tissue extracts by ELISA.
Schmitt M; Sturmheit AS; Welk A; Schnelldorfer C; Harbeck N
Methods Mol Med; 2006; 120():245-65. PubMed ID: 16491606
[TBL] [Abstract][Full Text] [Related]
18. Both the cytosols and detergent extracts of breast cancer tissues are suited to evaluate the prognostic impact of the urokinase-type plasminogen activator and its inhibitor, plasminogen activator inhibitor type 1.
Jänicke F; Pache L; Schmitt M; Ulm K; Thomssen C; Prechtl A; Graeff H
Cancer Res; 1994 May; 54(10):2527-30. PubMed ID: 8168072
[TBL] [Abstract][Full Text] [Related]
19. The p75(NTR) metastasis suppressor inhibits urokinase plasminogen activator, matrix metalloproteinase-2 and matrix metalloproteinase-9 in PC-3 prostate cancer cells.
Nalbandian A; Djakiew D
Clin Exp Metastasis; 2006; 23(2):107-16. PubMed ID: 16912916
[TBL] [Abstract][Full Text] [Related]
20. High level of urokinase-type plasminogen activator is a new prognostic marker in patients with gastric carcinoma.
Cho JY; Chung HC; Noh SH; Roh JK; Min JS; Kim BS
Cancer; 1997 Mar; 79(5):878-83. PubMed ID: 9041148
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]